Moderate–Severe · Blistering in childhood, thick scale in adulthood

Epidermolytic Ichthyosis

Also called EHK, Epidermolytic Hyperkeratosis, or Bullous Congenital Ichthyosiform Erythroderma (BCIE). Caused by mutations in keratin genes KRT1 or KRT10. 2025 EDD name: KRT1-nEDD / KRT10-nEDD.

1 in 200–300k

Prevalence

Autosomal Dominant

Inheritance (most)

KRT1 / KRT10

Genes

Keratin 1 & 10

Proteins affected

Build My Routine Not sure of your type? →

What is Epidermolytic Ichthyosis?

Epidermolytic Ichthyosis is a rare genetic skin condition where the proteins that hold skin cells together — keratins 1 and 10 — are faulty. When skin experiences friction or heat, the cells break down, causing blistering. Over time, as the skin tries to protect itself, it builds up thick, warty scale instead.

There's a shift through life: blistering dominates in infancy and childhood, then reduces. Thick hyperkeratosis becomes the main challenge in adulthood. Both phases come with their own management priorities.

One of the most significant (and often undiscussed) features of EI is odour — bacteria colonise the moist scale in skin folds, causing a distinctive smell that affects quality of life significantly. This is manageable but requires daily attention.

EDD 2025 reclassification: EI is now classified under the nEDD (non-syndromic Epidermal Differentiation Disorder) group as KRT1-nEDD (KRT1 mutations) or KRT10-nEDD (KRT10 mutations). Old names — EHK, BCIE, bullous ichthyosiform erythroderma — are all the same condition.

KRT1 mutations

More severe palmoplantar keratoderma (PPK) — thick skin on palms and soles
Dominant inheritance (one copy causes disease)
OMIM #113800

KRT10 mutations

Milder PPK — KRT10 is less expressed on palms/soles
Mostly dominant (AD), rare recessive form (AR) also exists
OMIM #620150 (AD), #620707 (AR)

De novo mutations are common. Around 50% of EI cases have no family history — the mutation happened spontaneously. If you're the only person in your family with EI, this is likely why.

Daily Routine

EI management has two phases. In blistering-active periods, the goal is preventing friction and infection. In stable hyperkeratotic periods, it shifts to scale removal and odour control.

Gentle warm shower (5 mins) — tepid water, not hot. Use a gentle non-soap cleanser. Pat, don't rub dry.

Emollient within 3 minutes — apply while skin is still damp. Epaderm, Hydromol, or 50:50 white soft paraffin generously over entire body.

Antibacterial wash to skin folds — dilute chlorhexidine wash or Hibiscrub (0.5–1% dilution) applied to armpits, groin, and other fold areas. Leave 1 min, rinse. This is your primary odour management tool.

Urea 10–20% cream to thick scale areas — especially elbows, knees, shins. Apply after main emollient has absorbed (5 mins).

Loose, soft clothing — avoid tight waistbands, rough fabrics, anything that creates friction over active skin areas. Cotton or bamboo where possible.

Medication Options

Always discuss medications with your dermatologist. Blistered or eroded skin changes what's appropriate.

Medication	Use in EI	Key Notes	NHS?
Emollients (50:50, Epaderm, Hydromol)	Daily barrier maintenance, scale softening	First line — apply generously 2–3× daily. Flammable with open flames.	✅ Free
Urea 10–40% cream	Thick scale keratolysis	Do NOT apply to blistered or open areas — stings severely. Start low (10%), increase slowly.	✅ Free
Acitretin (Neotigason)	Systemic retinoid — reduces hyperkeratosis	Particularly effective for KRT10 mutations. Not safe in pregnancy/breastfeeding. 3-year contraception requirement after stopping.	✅ NHS (specialist Rx)
Topical retinoids (tazarotene/tretinoin)	Localised thick scale	Only on non-blistered areas. May worsen acute blistering. Use cautiously.	Off-label
Chlorhexidine wash / Hibiscrub (dilute)	Antibacterial — odour and infection prevention	Daily to skin folds. Reduces Staph aureus colonisation which drives odour and infections.	✅ OTC/NHS
Mupirocin (Bactroban) ointment	Secondary infection on blistered areas	Topical antibiotic for localised skin infection. Not for prolonged use (resistance risk).	✅ NHS
Flucloxacillin / erythromycin (oral)	Secondary skin infection	For spreading infection or signs of cellulitis. Seek urgent GP/dermatology.	✅ NHS

Common Problems

Blistering — what to do and what not to do

Blistering in EI is caused by keratin breakdown under friction, heat, or trauma. It's not infection initially — but infected blisters look the same. Leave blisters intact if possible. If draining, do it sterile at the edge, leaving the roof in place. Cover with non-adherent dressings (Mepitel One is highly recommended). Seek medical help if blisters spread rapidly, are hot, or are accompanied by fever.

Odour — the honest guide

This is the most significant but least discussed feature of EI. Bacteria — primarily Staphylococcus aureus — colonise warm, moist scale in skin folds and produce the characteristic odour. Daily dilute chlorhexidine or Hibiscrub wash to armpits, groin, behind knees, and other fold areas is the most effective intervention. Loose breathable clothing helps. Diet can have a minor effect (some patients note improvements reducing processed foods). Be honest with your dermatologist — this is a medical issue, not a hygiene failure.

Palmoplantar Keratoderma (PPK) — thick skin on hands and feet

PPK is more common and more severe in KRT1 mutations. Thick scale on palms and soles causes pain, fissuring, and difficulty with gripping and walking. Salicylic acid 5–6% gel or ointment is effective overnight under occlusion (socks/cotton gloves). Urea 30–40% cream is useful on very thick areas. A podiatrist can help with plantar management — request referral via GP. Acitretin improves PPK significantly in many patients.

Secondary infections — spotting them early

EI patients have higher infection rates than other ichthyosis types — disrupted skin barrier plus bacteria-rich scale. Signs: blisters that spread rapidly, increasing redness or warmth around a wound, fever, pain beyond normal levels, pus. Act fast — skin infections in EI can spread quickly. GP same day or urgent dermatology. Do not rely on antiseptic alone if cellulitis is suspected.

Heat and sweating

Heat increases blistering in EI — friction plus moisture from sweat is a trigger. Air conditioning, cool showers after exertion, and loose clothing are critical. Exercise can be managed with loose moisture-wicking layers and a post-exercise immediate emollient and antibacterial routine. Inform employers and schools about heat sensitivity — reasonable adjustments are a legal right under the Equality Act 2010.

8-Week Management Protocol

This protocol assumes stable (non-acute-blistering) phase. If actively blistering, focus on infection prevention first.

Weeks 1–2 — Foundation

Goal: Establish consistent twice-daily emollient and daily antibacterial fold wash. Build the routine before adding anything else. Track blistering triggers (friction, heat, fabrics).

Weeks 3–4 — Keratolytic introduction

Goal: Introduce urea 10% on thickened (non-blistered) areas only. Add gentle scale removal in evening soak. If prescribed acitretin, begin at lower dose (0.3 mg/kg/day).

Weeks 5–6 — Odour management optimisation

Goal: Assess whether fold antibacterial routine is sufficient. If odour persists, consider increasing frequency or switching chlorhexidine concentration. Discuss with dermatologist if no improvement.

Weeks 7–8 — Maintenance

Goal: Simplify to sustainable minimum effective routine. Identify personal triggers. Write up your management summary to share with new doctors or for travel. Review acitretin dose with dermatologist if using.

What to Expect Over Time

Infancy and childhood

Birth to early childhood is often the most challenging period. Generalised erythroderma, blistering, and skin denudation at birth. Blistering dominates and is frequent. Infection risk is high. With careful management it reduces significantly.

Adolescence and adulthood

Blistering typically reduces with age. Thick, warty scale becomes the dominant feature. Odour management becomes more important. Acitretin becomes a useful long-term option for many adults. The condition is manageable — most adults with EI lead full, active lives.

Key Research

EI Cure Project

The EI Cure Project is an international research consortium dedicated to finding gene therapy treatments for Epidermolytic Ichthyosis. They connect researchers, clinicians, and patients. If you have EI, registering with them increases your chance of being contacted about trials.

eicureproject.com →

2025 JEADV Cohort Study

Frommherz et al (2025) published the largest German EI cohort study, confirming that skin pain, odour, and infections are the primary burden-of-disease drivers. KRT1 mutations associate with more severe PPK; KRT10 with milder involvement. (Journal of the European Academy of Dermatology and Venereology)

Read paper →

Retinoids and KRT10 mutations (2024)

Li & Törmä (2024, Acta Derm Venereol) showed retinoids reduce keratin aggregate formation in heat-stressed keratinocytes from KRT10 mutation patients, helping explain the mechanism behind retinoid benefit in EI.

Alitretinoin in women of childbearing age (2024)

A 2024 case series (Dermatology) confirmed alitretinoin as a viable alternative to acitretin in women who cannot tolerate the 3-year teratogenic restriction — shorter 1-month washout with comparable efficacy.